Gut and liver
Cure8 research brief
Why This Matters
The study highlights higher risks of tuberculosis and depression/anxiety associated with advanced therapies—especially anti-TNF agents—which are relevant safety concerns for people with IBD and their care teams. It may affect screening and monitoring practices.
Who Should Pay Attention
Clinicians prescribing biologics/small molecules, patients on anti-TNF therapy or other advanced therapies, IBD researchers.
Study Snapshot
Story typeResearch paper
Evidence typeObservational study
Source depthJournal abstract
What To Know
This multicenter retrospective study used a common data model across 13 hospitals to compare adverse events (AEs) in IBD patients receiving advanced therapies (ATs) versus those not receiving ATs. The abstract reports higher risks of tuberculosis and depression/anxiety in patients on ATs overall, and specifically with anti-TNF agents.
Small-molecule agents did not show increased risks for most AEs and had a lower observed malignancy incidence, though event counts were small. The study is observational and used propensity-score methods to adjust for differences between groups; that reduces but does not eliminate bias from unmeasured confounding.
These findings describe associations, not proof that a drug caused an adverse event. If you take or prescribe anti-TNF therapy, this report reinforces the importance of TB screening and monitoring mental health during treatment. For newer small-molecule drugs the numbers were smaller, so the results are less certain.
Keep In Mind
Findings come from a multicenter retrospective common-data-model analysis (abstract level). Observational design and small event numbers in some subgroups limit causal conclusions and precision.
Source Details
Review the original publication for the complete reporting, methods, and context.
Observational study
Evidence type derived from source or registry metadata.
PublicationGut and liver
AuthorsHyoung Il Choi, Myoungsuk Kim, Jung Rock Moon +7 more
InstitutionDepartment of Gastroenterology, Kyung Hee University Hospital at Gangdong, Seoul, Korea.
Study typeJournal article, observational study, multicenter study, comparative study
Indexed viaPubMed
Source typeResearch paper
PublishedJun 22, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
Real-World Data Show Efficacy of Risankizumab in Refractory Crohn's
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.